Results 181 to 190 of about 7,362 (230)

PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells. [PDF]

Cancers (Basel)
Knoll N, Somay K, Tiwari PB, Deniz E, Formen JSSK, Frye I, Nelson E, Wolf C, Toretsky JA, Üren A.   +9 more
europepmc   +1 more source

Evolving CRBN ligands enhance the drug-like properties of protein degraders. [PDF]

J Enzyme Inhib Med Chem
Ji XQ, Wang L, Dai XJ.
europepmc   +1 more source

On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases. [PDF]

J Med Chem
Weckesser J, Miletić N, Sivashanmugam SA, Ohmayer U, Steger M, Shashikadze B, Gehrtz P, Unzue Lopez A, Wegener A, Dietz TY, Hammann T, Hartung IV, Elson L, Němec V, Schwalm MP, Adhikari B, Wolf E, Krämer A, Müller S, Daub H, Knapp S.   +20 more
europepmc   +1 more source

Hydrophobic Tag Protein Degraders: An Emerging Therapeutic Strategy for Cancer. [PDF]

Pharmaceuticals (Basel)
Aguilera-Pineda T, Kumar S, Ghosal G, Natarajan A, Karpf AR.   +4 more
europepmc   +1 more source

A DoE-Dual centrifugation-driven screening platform for liposomal incorporation of poorly soluble APIs: Application to the PROTAC ACBI2. [PDF]

Int J Pharm X
Jaki M, Köll-Weber M, Lembeck J, Wittmann M, Süss R.   +4 more
europepmc   +1 more source

Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. [PDF]

J Hematol Oncol
Mahadevan D, Barve M, Mahalingam D, Parekh J, Kurman M, Strauss J, Tremaine L, Hromas R, Sills J, McCulloch J, Harkey J, Suberg S, Zimmerman L, Zheng G, Zhou D.   +14 more
europepmc   +1 more source

Design, Synthesis, Biological Studies and Putative Binding Mode of Novel Benzotriazolothalidomide Derivatives as Cereblon Ligands. [PDF]

Chem Biol Drug Des
Ganguly P, Kundu M, Sarkar T, Dcosta G, Banerjee K, Banerjee R, Hajra AK, Sahabuddin S, Basu S, Das A, Das S, Barik R, Ali MA.   +12 more
europepmc   +1 more source

Identification of Clofibric Acid as a Synoviolin (SYVN1) Ligand for Proteolysis-Targeting Chimera (PROTAC) Development. [PDF]

ACS Med Chem Lett
Warren J, Munakala A, Zientek KD, Kim K, Wilmarth PA, Reddy AP, Li BX, Xiao X.   +7 more
europepmc   +1 more source